(Q37867260)

24 August 2017

1 reference

title

Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients (English)

1 reference

24 August 2017

1 reference

Tammy M Winterboer

1

1 reference

PubMed ID

21507788

24 August 2017

Kassandra A Lecci

series ordinal

2

1 reference

PubMed ID

21507788

24 August 2017

Keith M Olsen

series ordinal

3

1 reference

24 August 2017

1 February 2010

1 reference

Journal of Pharmacy Practice

24 August 2017

1 reference

24 August 2017

23

1 reference

24 August 2017

1

1 reference

24 August 2017

6-18

1 reference

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

24 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

A primer on continuous renal replacement therapy for critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Sustained low efficiency dialysis in the continuous mode (C-SLED): dialysis efficacy, clinical outcomes, and survival predictors in critically ill cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Penetration of vancomycin into human lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Tissue concentrations: do we ever learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacodynamics and dosing of aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

How predictive is PK/PD for antibacterial agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Suboptimal aminoglycoside dosing in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Back to the future: using aminoglycosides again and how to dose them optimally

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

What have we learned from pharmacokinetic and pharmacodynamic theories?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Nephrotoxicity of vancomycin, alone and with an aminoglycoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Continuous infusion of beta-lactams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Stability of doripenem in vitro in representative infusion solutions and infusion bags

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacodynamic optimization of beta-lactams in the patient care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Clinical pharmacodynamics of quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacodynamics: relation to antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Pharmacokinetic issues for antibiotics in the critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190009356550

21 January 2018

Identifiers

DOI

10.1177/0897190009356550

1 reference

24 August 2017

1 reference

PubMed ID

21507788